Ranibizumab (Anti-VEGF Antibody)

Ranibizumab, also known as RG-6321, is a humanized anti-VEGF (vascular endothelial growth factor) monoclonal antibody fragment and can recognize all VEGFA isoforms (VEGF110, VEGF121, and VEGF165). Ranibizumab (sold under the name Lucentis), is now approved by the FDA for the treatment of AMD (age related macular degeneration). The interaction between VEGF (Vascular Endothelial Growth Factor) and its receptor VEGFR is an important mediator of angiogenesis as well as endothelial cell survival and proliferation. VEGFR2 is a receptor tyrosine kinase that plays a major role in cellular responses driven by VEGF. Targeting the kinase activity of VEGFR2 has been an attractive tool in cancer therapy based on its anti-angiogenesis effects. In addition to the kinase inhibitors, humanized monoclonal antibodies interfering with VEGF/VEGFR2 interaction have been also developed for anti-cancer treatments. The use of antibodies, such as Ranibizumab (sold under the name Lucentis), is now approved by the FDA for the treatment of AMD (age related macular degeneration).